Evaluation Of The H2FPEF And HFA-PEFF Diagnostic Scores In Obese Hemodynamically Confirmed HFpEF
Heart failure with preserved ejection fraction (HFpEF) was once predominantly a disease of older patients with hypertension and left ventricular hypertrophy. However, the prevalent phenotype has markedly changed to one of obesity and metabolic syndrome. Scoring algorithms derived from prior common HFpEF phenotypes, including the H2FPEF and HFA-PEFF scores, have yet to be evaluated in a predominantly obese HFpEF cohort. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Soumya Vungarala, Vivek Jani, Joban Vaishnav, Virginia Hahn, David Kass, Kavita Sharma Tags: 080 Source Type: research

Sacubitril/valsartan Vs Ace Inhibitor Use In Patients With Heart Failure With Reduced Ejection Fraction And New York Heart Association - 4 Symptoms; A Propensity Score Matched Analysis
Sacubitril/Valsartan is the first-line medication for patients with heart failure with reduced ejection fraction (HFrEF), evidence for which has come largely from the Paradigm-HF trial. Patients with New York Heart Association - 4 symptoms (NYHA-4) were underrepresented in this landmark trial with them being (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Bharat Rawlley, Andres Cordova Sanchez, Debanik Chaudhuri Tags: 081 Source Type: research

Evaluation Of Pharmacist-managed Titration Of Guideline-directed Medical Therapy In Patients With Heart Failure With Reduced Ejection Fraction Utilizing Telehealth - A Pilot Study
Patients with heart failure with reduced ejection fraction (HFrEF) are commonly not prescribed target doses of guideline-directed medical therapy (GDMT). Pharmacist-managed adjustment of GDMT, utilizing telehealth, may improve GDMT titration. The purpose of this study was to evaluate GDMT utilization and titration in patients with HFrEF enrolled in a pharmacist-led GDMT telehealth clinic. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Nathan J. Verlinden, Brandi Steady, Ronald Campbell, Azam Hadi, Matthew Lander, Manreet Kanwar Tags: 082 Source Type: research

Does Duration Of Gdmt Up-titration Affect The Percentage Of Hfimpef Attainment?
Heart failure with improved ejection fraction (HFimpEF) is defined as heart failure with previous LVEF ≤40% and a follow-up LVEF>40%. Although it does not reflect full myocardial recovery, HFimpEF is a marker of GDMT's effectiveness. Not all patients, however, are able to attain HFimpEF, and the factors behind the development of HFimpEF remain under investigation. One of those factors is the duration of GDMT up-titration, that is, the time between GDMT initiation and reaching maximally tolerated dose. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Hassan Dehaini, Jasmin Ortiz, Megan Valante, Kathir Balakumaran Tags: 083 Source Type: research

Is Right Heart Catheterization Still Necessary For Assessing Hemodynamic Parameters In Acute Heart Failure? Insights From Propensity-Matched Analysis
The impact of right heart catheterization (RHC) on patients with acute heart failure is a crucial topic in cardiology. Although RHC is valuable in diagnosing various hemodynamic parameters, it also poses risks. Hence, it is important to evaluate its effects on patients to decide whether alternative diagnostic methods should be considered. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Omar Al Wahadneh, Apoorva Raju, Ahmed Maraey, Hadeer Elsharnoby, Shazia Aziz Tags: 084 Source Type: research

Evaluating Eligibility Criteria Of The Strong-hf Trial For Patients In Real-world Setting, An Experience From An Advanced Heart Failure Program In A Tertiary Care Health System
The STRONG-HF trial has demonstrated that an intensive treatment strategy involving the rapid up-titration of guideline-directed medication therapy (GDMT) and close patient monitoring can significantly reduce the incidence of all-cause death or readmission for acute heart failure (AHF) within 180 days compared to standard care. Nonetheless, there are concerns regarding the trial's selection criteria potentially restricting the external validity of this study, which may result in only a smaller group of patients being eligible for this novel intensive treatment strategy. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Hua Ling, Ugochukwu Egolum Tags: 085 Source Type: research

Short Term Impact Of An Inpatient Electronic Medical Record Pathway On Heart Failure Outcomes
Heart failure (HF) is a leading cause of hospitalization in the United States, and readmission rates and mortality following hospitalization remain elevated. Electronic medical record (EMR) technology has facilitated the development of tools to improve disease management. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Elnaz Esmati, Jeremy Pollock, Charles Callahan, Carol Wade, David Marchese, Meredith Truss, Megan Walker, Gautam Ramani Tags: 086 Source Type: research

Baseline Characteristics Of Patients With Transthyretin Cardiac Amyloidosis Enrolled In The Patisiran Expanded Access Program
Transthyretin-mediated (ATTR) amyloidosis is a progressive, multisystem, fatal disease. Treatment for patients with ATTR cardiac amyloidosis is limited, with only the transthyretin (TTR) stabilizer, tafamidis, FDA approved for the treatment of the cardiomyopathy of ATTR amyloidosis in the US. Patisiran, an RNA interference therapeutic, is approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy and is being investigated in APOLLO-B for ATTR cardiac amyloidosis. After positive APOLLO-B study results and multiple requests for compassionate use, an expanded access program (EAP) was established and is ongo...
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Naveen Saha, Zubair Shah, Mazen A. Hanna, Andriana Nikolova, Colleen Moffitt, Catherine Summers, Kelley Capocelli, Brian M. Drachman Tags: 087 Source Type: research

Myocarditis As A Manifestation Of Catastrophic Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) has been well studied and has known association with Libman Sacks endocarditis, accelerated atherosclerotic disease, valvular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension, and left ventricular dysfunction. Although APS has been associated with lupus myocarditis, there has not been reports of APS myocarditis. Here we present a unique case of bilateral adrenal hemorrhage and myocarditis secondary to APS. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Mica Alex, Modar Alom, Amro Alsaid, Gregory Milligan, Nitin Kabra, David Rawitscher, Aasim Afzal Tags: 088 Source Type: research

Incidence And Treatment Of Atrial Fibrillation In Cardiac Amyloidosis
Atrial fibrillation and/or flutter (AF/flutter) are common in cardiac amyloidosis. Treatment options for AF/flutter include rate control or rhythm control with antiarrhythmic medications, cardioversion, and catheter ablation, though the relative benefit and efficacy of these therapies remain unclear. The purpose of this retrospective study was to examine the prevalence of AF in cardiac amyloidosis at our center as well as the frequency and efficacy of the varied management strategies. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Jack Haslett, Nikhil Patel, Jon Kobashigawa, Michelle Kittleson, Jignesh Patel Tags: 089 Source Type: research

The Missed Culprit For A Complex Case Of Non-ischemic Cardiomyopathy
We present a rare case of HCQ-induced cardiomyopathy due to chronic HCQ use. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Mohamed Salah Mohamed, Katrina Wojciechowski, Muhammad Osama, Anas Hashem, Jayesh Patel, Amir Mahmoud, Ali Abdelhay, Prakash Upreti, Scott Feitell, Soidjon Khodjaev Tags: 090 Source Type: research

Younger Adults Have Discordant Heart Failure Symptoms
Symptoms of a heart failure (HF) exacerbation are numerous, distressing, and a major reason for hospitalization among patients with HF. As HF symptoms rarely occur in isolation, studying symptoms as clusters might be more effective than single symptoms in relationship to patient outcomes. Recent research has focused on the relationship between HF symptom clusters and mortality, hospitalization, functional status and quality of life. No studies to date have focused on the relationship of symptom clusters to delay in seeking treatment. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Kristen A. Sethares, Corrine Jurgens Tags: 091 Source Type: research

The Comparative Effectiveness Between Angiotensin Receptor-neprilysin Inhibitor And Renin-angiotensin System Blockade In Patient With Heart Failure With Reduced Ejection Fraction: Nationwide Medication Adherence Study
The objectives of this study were to compare the effectiveness of ARNI and renin-angiotensin system (RAS) blockade in HFrEF and investigate the influence of medication adherence on outcomes. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Dong-Hyuk Cho, Jimi Choi, Jong-Chan Youn, Byung-Su Yoo Tags: 092 Source Type: research

Proteomic Correlates Of Urinary Protein Creatinine Ratio In Heart Failure With Preserved Ejection Fraction
Proteinuria is common in heart failure with preserved ejection fraction (HFpEF) but its biologic correlates are poorly understood. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Sushrima Gan, Lei Zhao, Oday Salman, Zhaoqing Wang, Christina Ebert, Joe David Azzo, Marie Joe Dib, Payman Zamani, Jordana (Jordy) Cohen, Karl Kammerhoff, Peter Schafer, Dietmar Seiffert, David Gordon, Thomas Cappola, Julio Chirinos Tags: 093 Source Type: research

Early Identification Of Explicit Treatment Strategies And Outcomes In Cardiogenic Shock
Patient treatment strategies differ in cardiogenic shock (CS) due to variable patient demographics, comorbidities, center resources, and caregiver support. Given the high in-patient mortality and complex care associated with CS, early identification of treatment strategies may help align multidisciplinary care teams to provide more efficient care. To what extent clearly stated CS treatment strategies are proposed by the care team has not been well reported. In this single-center prospective cohort study, we aim to characterize the early treatment strategies for CS and the associated outcomes. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Hadi Beaini, Amit Saha, Sarah Godfrey, Lauren Truby, Nicholas Hendren, Jennifer Thibodeau, Elizabeth Hardin, Faris Araj, Hurst Hall, Mark Drazner, Mary Jane Farr Tags: 094 Source Type: research